Is Cytosorbents Corporation (CTSO) a Buy, Sell, or Hold?
Cytosorbents Corporation
NASDAQ:CTSO
$0.3885 USD
$0.01 (2.24%)
- Volume
- 75.28K
- Average Volume
- 155.69K
- Market Capitalization
- $24.41M
- P/E Ratio
- -2.08
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $1.22
- Year Low
- $0.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.09
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Phillip Chan |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | CTSO |
| CUSIP | 23283X206 |
| CIK | 0001175151 |
| Web | https://www.cytosorbents.com |
| Phone | 732 329 8885 |
| Currency | USD |
| Employees | 129 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 8.64 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.09 |
| Quick Ratio | 0.81 |
| Cash Ratio | 0.30 |
Sales & Book Value
| Annual Sales | $37.06M |
| Price / Sales | 0.66 |
| Cash Flow | -0.16 |
| Price / Cash Flow | -2.39 |
| Price / Book | 11.11 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.13 |
| Trailing P/E Ratio | -2.08 |
| PEG Ratio | 0.31 |
| P/E Growth | 0.31 |
| Net Income | $-8.2M |
| Net Margin | -31.85% |
| Pretax Margin | -32.93% |
| Return on Equity | -165.13% |
| Return on Assets | -29.21% |
Financials Score
| AltmanZ Score | -10.37 |
| Piotroski Score | 3.00 |
| Working Capital | 1.45M |
| Total Assets | 40.56M |
| Ebit | -9.39M |
| Market Cap | 24.4M |
| Total Liabilities | 38.37M |
Poll Results
About Cytosorbents Corporation (NASDAQ:CTSO) Stock
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and ... other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
2026-06-18 08:46:00
PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Life Sciences Forum hosted by VirtualInvestorConferences.com on Wednesday, June 24, 2026 and provide an overview and update on the Company. Following the presentation, Zacks Analyst Mr. Thomas Kerr will host a brief Q&A session with Dr. Chan and Mr. Peter Mariani, Chief Financial Officer.
Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript
2026-05-13 19:30:49
Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript
2026-05-13 16:00:00
PRINCETON, N.J., May 13, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2026, recent business highlights, and provides a regulatory update.
CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
2026-04-30 07:00:00
PRINCETON, N.J., April 30, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2026 financial results and recent business highlights after the market close on Wednesday, May 13, 2026.
Frequently Asked Questions
-
What is the current Cytosorbents Corporation (CTSO) stock price?
-
Cytosorbents Corporation(NASDAQ:CTSO) stock price is $0.3885 in the last trading session. During the trading session, CTSO stock reached the peak price of $1.22 while $0.35 was the lowest point it dropped to. The percentage change in CTSO stock occurred in the recent session was 2.24% while the dollar amount for the price change in CTSO stock was $0.01.
-
CTSO's industry and sector of operation?
-
The NASDAQ listed CTSO is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of CTSO?
-
Jodi Hoover | Executive
Kathleen Bloch | Advisor
Christian Steiner | Executive Vice President of Sales & Marketing
Efthymios N. Deliargyris FACC FESC FSCAI | Chief Medical Officer
Phillip Chan | Chief Executive Officer & Director -
How many employees does CTSO have?
-
Number of CTSO employees currently stands at 129. CTSO operates from 305 College Road East, Princeton, NJ 08540, US.
-
Link for CTSO official website?
-
Official Website of CTSO is: https://www.cytosorbents.com
-
How do I contact CTSO?
-
CTSO could be contacted at phone #732 329 8885 and can also be accessed through its website. CTSO operates from 305 College Road East, Princeton, NJ 08540, US.
-
How many shares of CTSO are traded daily?
-
The average number of CTSO shares traded daily for last 3 months was 155.69K.
-
What is the market cap of CTSO currently?
-
The market value of CTSO currently stands at $24.41M with its latest stock price at $0.3885